Drug profile · INN
osimertinib mesylate
TAGRISSO
osimertinib mesylate (TAGRISSO) is a epidermal growth factor receptor erbb1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — osimertinib mesylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
osimertinib mesylate (TAGRISSO) is a epidermal growth factor receptor erbb1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is osimertinib mesylate?
osimertinib mesylate (TAGRISSO) is a epidermal growth factor receptor erbb1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for osimertinib mesylate?
TAGRISSO is a marketed brand name for osimertinib mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of osimertinib mesylate?
osimertinib mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.